Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110214 · ClinicalTrials.gov registry record · Phase 3
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
A Phase 3 study of Recurrent Prostate Cancer and Stage IV Prostate Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 1,050
- Enrollment target
- 2
- Study locations
NCT00110214: Completed Phase 3 study of Recurrent Prostate Cancer and Stage IV Prostate Cancer, sponsored by National Cancer Institute (NCI).
NCT00110214 is a Phase 3 study of Recurrent Prostate Cancer and Stage IV Prostate Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 1,050 participants, above the 89-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (1080% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00110214, a Phase 3 study of Recurrent Prostate Cancer and Stage IV Prostate Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,050 participants
- Enrollment target
- 2
- Study locations
Study Summary
This randomized phase III trial is studying docetaxel, prednisone, and bevacizumab to see how well they work compared to docetaxel and prednisone in treating patients with prostate cancer that did not respond to hormone therapy. Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether docetaxel, prednisone, and bevacizumab are more effective than docetaxel and prednisone in treating prostate cancer.
Primary Outcome
Overall Survival (OS) was measured from the date of randomization to date of death due to any cause. OS was estimated using the Kaplan Meier method.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG prednisone
- OTHER placebo
- DRUG docetaxel
- BIOLOGICAL bevacizumab
Study Locations (2)
Connecticut
- Yale University - New Haven
Illinois
- Cancer and Leukemia Group B - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,050 participants |
| Start Date | 2005-04 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
What the finished NCT00110214 record still lists
NCT00110214 is an interventional study that assigns participants to a tested intervention. Its 1,050 participants enrollment target places it among the larger protocols in the corpus, above the 89-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (1080% higher).
The record links to 4 conditions, with Recurrent Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00110214 reports a single indexed study location in Connecticut, Illinois.
Frequently Asked Questions
What is clinical trial NCT00110214 about?
NCT00110214 is a clinical study titled "Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy". This randomized phase III trial is studying docetaxel, prednisone, and bevacizumab to see how well they work compared to docetaxel and prednisone in treating patients with prostate cancer that did not respond to hormone therapy. Drugs used in chemotherapy, such as docetaxel and prednisone, work in d...
What is the current status of trial NCT00110214?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,050 participants. The study started on 2005-04. Estimated completion is 2011-08.
What conditions does trial NCT00110214 study?
This clinical trial studies the following conditions: Recurrent Prostate Cancer, Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Hormone-Resistant Prostate Cancer.
What interventions are being tested in trial NCT00110214?
The interventions under investigation include: laboratory biomarker analysis (OTHER), prednisone (DRUG), placebo (OTHER), docetaxel (DRUG), bevacizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00110214?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00110214 being conducted?
This trial has 2 study locations across Connecticut, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00110214's enrollment target sits among peer trials
1,050 1st of 21 higher than 21 of 21 other Recurrent Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
RECRUITING · Phase 2
-
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
RECRUITING · Phase 2
-
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
RECRUITING · Phase 1
-
Tumor Microenvironment Analysis of Prostate Cancer Metastasis
RECRUITING
-
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
RECRUITING · Phase 1
-
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04505618 · 1,050 participants · NA
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
- NCT04511806 · 1,050 participants
Childhood Cancer Predisposition Study (CCPS)
- NCT05028972 · 1,050 participants · NA
Hearing Impairment, Strategies and Outcomes in VA Emergency Departments
- NCT05915377 · 1,050 participants · NA
Researching Efficient Approaches to Delirium Identification-Sustaining Effective Translation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia